Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.83 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14062037 | 0.94 | DGAT1 (0.80) | DGAT1MCHR1ITGB3ITGA2BNPC1 | |
| SCHEMBL14060436 | 0.91 | DGAT1 (1.00) | DGAT1MCHR1ITGB3ITGA2BNPC1 | |
| SCHEMBL17200553 | 0.91 | DGAT1 (0.82) | DGAT1MCHR1ITGB3ITGA2BNPC1 | |
| SCHEMBL17200564 | 0.89 | DGAT1 (0.83) | DGAT1MCHR1ITGB3ITGA2BNPC1 | |
| SCHEMBL17200580 | 0.88 | DGAT1 (0.68) | DGAT1MCHR1RAB9A | |
| SCHEMBL17211825 | 0.86 | DGAT1 (0.69) | DGAT1MCHR1ITGB3ITGA2BNPC1 | |
| SCHEMBL17200605 | 0.86 | DGAT1 (0.78) | DGAT1MCHR1ITGB3ITGA2B | |
| SCHEMBL14062390 | 0.84 | DGAT1 (0.76) | DGAT1MCHR1ITGB3ITGA2B | |
| SCHEMBL17200609 | 0.84 | DGAT1 (0.82) | DGAT1MCHR1ITGB3ITGA2BNPC1 | |
| SCHEMBL17200593 | 0.84 | DGAT1 (0.82) | DGAT1MCHR1ITGB3ITGA2BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723332-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-03-02 | — | — | EP | claimed |
| EP-2723332-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| EP-2723332-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | DGAT1 1/4885MCHR1 2800/4885ITGB3 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.